SAN DIEGO--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today reported data demonstrating that prolonged treatment with ADCETRIS beyond 16 cycles of therapy was associated with clinically meaningful durations of response with a manageable safety profile. In addition, data were presented showing that ADCETRIS is a viable option for reducing tumor burden prior to allogeneic stem cell transplant. The data were presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 10-13, 2011 in San Diego, CA. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30.
